|
51
|
Tordjman S, Najjar I, Bellissant E, Anderson GM, Barburoth M, Cohen D, Jaafari N, Schischmanoff O, Fagard R, Lagdas E, Kermarrec S, Ribardiere S, Botbol M, Fougerou C, Bronsard G, Vernay-Leconte J. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 2013; 14:20508-42. [PMID: 24129182 PMCID: PMC3821628 DOI: 10.3390/ijms141020508] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 09/03/2013] [Accepted: 09/13/2013] [Indexed: 12/31/2022] Open
Abstract
Abnormalities in melatonin physiology may be involved or closely linked to the pathophysiology and behavioral expression of autistic disorder, given its role in neurodevelopment and reports of sleep-wake rhythm disturbances, decreased nocturnal melatonin production, and beneficial therapeutic effects of melatonin in individuals with autism. In addition, melatonin, as a pineal gland hormone produced from serotonin, is of special interest in autistic disorder given reported alterations in central and peripheral serotonin neurobiology. More specifically, the role of melatonin in the ontogenetic establishment of circadian rhythms and the synchronization of peripheral oscillators opens interesting perspectives to ascertain better the mechanisms underlying the significant relationship found between lower nocturnal melatonin excretion and increased severity of autistic social communication impairments, especially for verbal communication and social imitative play. In this article, first we review the studies on melatonin levels and the treatment studies of melatonin in autistic disorder. Then, we discuss the relationships between melatonin and autistic behavioral impairments with regard to social communication (verbal and non-verbal communication, social interaction), and repetitive behaviors or interests with difficulties adapting to change. In conclusion, we emphasize that randomized clinical trials in autism spectrum disorders are warranted to establish potential therapeutic efficacy of melatonin for social communication impairments and stereotyped behaviors or interests.
Collapse
Affiliation(s)
- Sylvie Tordjman
- Hospital-University Department of Child and Adolescent Psychiatry, Guillaume Régnier Hospital, Rennes 1 University, Rennes 35000, France; E-Mails: (I.N.); (E.L.); (S.K.); (S.R.); (J.V.-L.)
- Laboratory of Psychology of Perception, CNRS UMR 8158, Paris 75270, France; E-Mail:
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +33-6-15-38-07-48; Fax: +33-2-99-64-18-07
| | - Imen Najjar
- Hospital-University Department of Child and Adolescent Psychiatry, Guillaume Régnier Hospital, Rennes 1 University, Rennes 35000, France; E-Mails: (I.N.); (E.L.); (S.K.); (S.R.); (J.V.-L.)
| | - Eric Bellissant
- Inserm CIC 0203 Clinical Investigation Centre, University Hospital, Rennes 1 University, Rennes 35033, France; E-Mails: (E.B.); (C.F.)
- Department of Clinical Pharmacology, University Hospital, Rennes 1 University, Rennes 35033, France
| | - George M. Anderson
- Laboratory of Developmental Neurochemistry, Yale Child Study Center, New Haven, CT 06519, USA; E-Mail:
- Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06519, USA
| | - Marianne Barburoth
- Laboratory of Psychology of Perception, CNRS UMR 8158, Paris 75270, France; E-Mail:
| | - David Cohen
- Hospital-University Department of Child and Adolescent Psychiatry, Pitié-SalpétrièreHospital, Paris 6 University, Paris 75013, France; E-Mail:
| | - Nemat Jaafari
- CIC INSERM U 802, CHU de Poitiers, Unité de recherche clinique intersectorielle en psychiatrie du Centre Hospitalier Henri Laborit, Poitiers 86022, France; E-Mail:
| | - Olivier Schischmanoff
- INSERM UMR U978, University of Paris 13, Bobigny 93009, France; E-Mails: (O.S.); (R.F.)
- Laboratoire de Biochimie et Biologie Moléculaire, Hôpital Avicenne, APHP, Bobigny 93009, France
| | - Rémi Fagard
- INSERM UMR U978, University of Paris 13, Bobigny 93009, France; E-Mails: (O.S.); (R.F.)
- Laboratoire de Biochimie et Biologie Moléculaire, Hôpital Avicenne, APHP, Bobigny 93009, France
| | - Enas Lagdas
- Hospital-University Department of Child and Adolescent Psychiatry, Guillaume Régnier Hospital, Rennes 1 University, Rennes 35000, France; E-Mails: (I.N.); (E.L.); (S.K.); (S.R.); (J.V.-L.)
| | - Solenn Kermarrec
- Hospital-University Department of Child and Adolescent Psychiatry, Guillaume Régnier Hospital, Rennes 1 University, Rennes 35000, France; E-Mails: (I.N.); (E.L.); (S.K.); (S.R.); (J.V.-L.)
| | - Sophie Ribardiere
- Hospital-University Department of Child and Adolescent Psychiatry, Guillaume Régnier Hospital, Rennes 1 University, Rennes 35000, France; E-Mails: (I.N.); (E.L.); (S.K.); (S.R.); (J.V.-L.)
| | - Michel Botbol
- Service Hospitalo-Universitaire de Psychiatrie de l’Enfant et de l’Adolescent de Brest, UBO, Brest 29238, France; E-Mail:
| | - Claire Fougerou
- Inserm CIC 0203 Clinical Investigation Centre, University Hospital, Rennes 1 University, Rennes 35033, France; E-Mails: (E.B.); (C.F.)
- Department of Clinical Pharmacology, University Hospital, Rennes 1 University, Rennes 35033, France
| | - Guillaume Bronsard
- Maison Départementale de l’Adolescent et Centre Médico-Psycho-Pédagogique, Conseil Général des Bouches-du-Rhône; Laboratoire de Santé Publique EA3279, Faculté de Médecine de la Timone, Marseille 13256, France; E-Mail:
| | - Julie Vernay-Leconte
- Hospital-University Department of Child and Adolescent Psychiatry, Guillaume Régnier Hospital, Rennes 1 University, Rennes 35000, France; E-Mails: (I.N.); (E.L.); (S.K.); (S.R.); (J.V.-L.)
| |
Collapse
|
|
52
|
Immunolocalization of Kisspeptin Associated with Amyloid-β Deposits in the Pons of an Alzheimer's Disease Patient. JOURNAL OF NEURODEGENERATIVE DISEASES 2013; 2013:879710. [PMID: 26317001 PMCID: PMC4437339 DOI: 10.1155/2013/879710] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/03/2013] [Revised: 04/23/2013] [Accepted: 04/24/2013] [Indexed: 02/03/2023]
Abstract
The pons region of the Alzheimer's disease (AD) brain is one of the last to show amyloid-β (Aβ) deposits and has been suggested to contain neuroprotective compounds. Kisspeptin (KP) is a hormone that activates the hypothalamic-pituitary-gonadal axis and has been suggested to be neuroprotective against Aβ toxicity. The localization of KP, plus the established endogenous neuroprotective compounds corticotropin releasing hormone (CRH) and catalase, in tissue sections from the pons region of a male AD subject has been determined in relation to Aβ deposits. Results showed Aβ deposits also stained with KP, CRH, and catalase antibodies. At high magnification the staining of deposits was either KP or catalase positive, and there was only a limited area of the deposits with KP-catalase colocalization. The CRH does not bind Aβ, whilst both KP and catalase can bind Aβ, suggesting that colocalization in Aβ deposits is not restricted to compounds that directly bind Aβ. The neuroprotective actions of KP, CRH, and catalase were confirmed in vitro, and fibrillar Aβ preparations were shown to stimulate the release of KP in vitro. In conclusion, neuroprotective KP, CRH, and catalase all colocalize with Aβ plaque-like deposits in the pons region from a male AD subject.
Collapse
|